Considerations for Colorectal Neoplasia Detection in Inflammatory Bowel Disease Clinical Trials

Overview

Journal Dig Dis

Specialty Gastroenterology

Date 2023 Sep 27

PMID 37757769

Authors

Mira M Yang

Keith Usiskin

Harris A Ahmad

Shabana Ather

Antoine Sreih

James B Canavan

Francis A Farraye

Christopher Ma

Affiliations

Soon will be listed here.

Abstract

Background: High-quality colonoscopic surveillance can lead to earlier and increased detection of colorectal neoplasia in patients with inflammatory bowel disease (IBD). In IBD clinical trials, endoscopy is used to assess mucosal disease activity before and after treatment but also provides an opportunity to surveil for colorectal neoplasia during follow-up.

Summary: Best practices for colorectal cancer identification in IBD clinical trials require engagement and collaboration between the clinical trial sponsor, site endoscopist and/or principal investigator, and central read team. Each team member has unique responsibilities for maximizing dysplasia detection in IBD trials.

Key Messages: Sponsors should work in accordance with scientific guidelines to standardize imaging procedures, design the protocol to ensure the trial population is safeguarded, and oversee trial conduct. The site endoscopist should remain updated on best practices to tailor sponsor protocol-required procedures to patient needs, examine the mucosa for disease activity and potential dysplasia during all procedures, and provide optimal procedure videos for central read analysis. Central readers may detect dysplasia or colorectal cancer and a framework to report these findings to trial sponsors is essential. Synergistic relationships between all team members in IBD clinical trials provide an important opportunity for extended endoscopic evaluation and colorectal neoplasia identification.

References

Har-Noy O, Katz L, Avni T, Battat R, Bessissow T, Yung D . Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. Dig Dis Sci. 2017; 62(11):2982-2990. DOI: 10.1007/s10620-017-4772-y. View

Deepak P, Hanson G, Fletcher J, Tremaine W, Pardi D, Kisiel J . Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointest Endosc. 2015; 83(5):1005-12. DOI: 10.1016/j.gie.2015.09.021. View

Gupta R, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A . Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133(4):1099-105. PMC: 2175077. DOI: 10.1053/j.gastro.2007.08.001. View

Parra-Blanco A, Nicolas-Perez D, Gimeno-Garcia A, Grosso B, Jimenez A, Ortega J . The timing of bowel preparation before colonoscopy determines the quality of cleansing, and is a significant factor contributing to the detection of flat lesions: a randomized study. World J Gastroenterol. 2006; 12(38):6161-6. PMC: 4088110. DOI: 10.3748/wjg.v12.i38.6161. View

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130(4):1030-8. DOI: 10.1053/j.gastro.2005.12.035. View

Kim H, Hernaez R, Sansgiry S, Waljee A, Scott F, Lewis J . Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022; 20(12):2848-2857.e2. PMC: 9489337. DOI: 10.1016/j.cgh.2022.02.048. View

Clarke W, Feuerstein J . Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. World J Gastroenterol. 2019; 25(30):4148-4157. PMC: 6700690. DOI: 10.3748/wjg.v25.i30.4148. View

Bye W, Ma C, Nguyen T, Parker C, Jairath V, East J . Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018; 113(12):1801-1809. PMC: 6768584. DOI: 10.1038/s41395-018-0354-7. View

Ahmad H, Berzin T, Yu H, Huang C, Mishkin D . Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf). 2014; 2(3):201-6. PMC: 4124272. DOI: 10.1093/gastro/gou033. View

10.

Klabunde C, Cronin K, Breen N, Waldron W, Ambs A, Nadel M . Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1611-21. PMC: 3153583. DOI: 10.1158/1055-9965.EPI-11-0220. View

11.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

12.

Eaden J, Mayberry J . Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol. 2000; 95(10):2710-9. DOI: 10.1111/j.1572-0241.2000.02297.x. View

13.

Murthy S, Feuerstein J, Nguyen G, Velayos F . AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology. 2021; 161(3):1043-1051.e4. DOI: 10.1053/j.gastro.2021.05.063. View

14.

Denters M, Deutekom M, Bossuyt P, Fockens P, Dekker E . Patient burden of colonoscopy after positive fecal immunochemical testing for colorectal cancer screening. Endoscopy. 2013; 45(5):342-9. DOI: 10.1055/s-0032-1326238. View

15.

Millan M, Gross P, Manilich E, Church J . Adenoma detection rate: the real indicator of quality in colonoscopy. Dis Colon Rectum. 2008; 51(8):1217-20. DOI: 10.1007/s10350-008-9315-3. View

16.

Adamina M, Feakins R, Iacucci M, Spinelli A, Cannatelli R, dHoore A . ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology. J Crohns Colitis. 2021; 15(7):1089-1105. DOI: 10.1093/ecco-jcc/jjab011. View

17.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

18.

Harewood G, Wiersema M, Melton 3rd L . A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy. Am J Gastroenterol. 2002; 97(12):3186-94. DOI: 10.1111/j.1572-0241.2002.07129.x. View

19.

Lee R, Tang R, Muthusamy V, Ho S, Shah N, Wetzel L . Quality of colonoscopy withdrawal technique and variability in adenoma detection rates (with videos). Gastrointest Endosc. 2011; 74(1):128-34. DOI: 10.1016/j.gie.2011.03.003. View

20.

Hurlstone D, Sanders D, Lobo A, McAlindon M, Cross S . Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005; 37(12):1186-92. DOI: 10.1055/s-2005-921032. View